ReST Therapeutics Receives FDA IND Clearance for PTSD Therapy RST-101 ReST Therapeutics announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug (IND) application for…
Otsuka Pharmaceutical Development & Commercialization Presents New Phase 3 Centanafadine Analyses Highlighting Broader ADHD Symptom Improvements Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization unveiled new post hoc…
Draig Therapeutics Highlights Positive Phase 1 DT-101 Results at ASCP Annual Meeting American Society for Clinical Psychopharmacology served as the stage for new clinical and translational data from Draig Therapeutics,…
BeOne Medicines Reports Phase 3 HERIZON-GEA Results Published in NEJM and Featured at ASCO 2026 BeOne Medicines has announced the publication and upcoming presentation of significant new clinical data from…
PharmaEssentia Names Eric Vogel as U.S. Commercialization Head in Preparation for Potential BESREMi® Launch in Essential Thrombocythemia PharmaEssentia Corporation has announced the appointment of Eric Vogel as the company’s new…
Secretome Therapeutics Secures $30 Million Series A Financing Led by RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics has announced the successful completion of a $30 million…
Cosm Medical Enters Licensing and Collaboration Agreement to Advance Personalized Gynethotics™ Devices for Post-Surgical Pelvic Recovery Cosm Medical Corp. has announced a new licensing and collaboration agreement with Duke Health…
Stallergenes Greer Foundation Honors Advances in Allergy Innovation Through 2025 Award Program Stallergenes Greer Foundation has announced the recipients of its 2025 Science Awards for Allergy, recognizing four researchers whose…
New Research on Headache Treatments, Biomarkers, and the Gut-Brain Connection to Be Featured at the American Headache Society® 68th Annual Scientific Meeting American Headache Society is preparing to host its…
Daiichi Sankyo Europe Highlights Broad EAS Congress 2026 Data Presentations Supporting Patient-Centred Cardiovascular Care Daiichi Sankyo Europe has announced a major scientific presence at the upcoming European Atherosclerosis Society Congress…
LINZESS® (linaclotide) Receives FDA Approval for Children Aged 2 and Older with Functional Constipation Ironwood Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an expanded indication…
Arrowhead Pharmaceuticals Unveils Encouraging Clinical Cardiometabolic Findings at the 94th European Atherosclerosis Society Congress Arrowhead Pharmaceuticals has presented new clinical findings supporting the broader use of plozasiran, its investigational small…